Answers are grounded in this paper and cite their sources.
The LMR might be an independent prognostic marker for TTR in stage III colon cancer patients. Our results further suggest that high-risk patients based on the LMR do not benefit from adjuvant chemotherapy. Independent validation of our findings is warranted.
No takes yet. Share an insight, caveat, or question.
Stotz et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: